treatment with LAIs. On the other hand, only 9.7 (15/158) % of patients thought that LAIs is "very suitable" or "suitable" for them. More than half of patients thought that LAIs are fewer side effects and more reliable therapeutic option. Conclusions: Our results clarified the gaps of attitudes toward LAIs between psychiatrists and patients with schizophrenia. Positive impression concerning side effects may promote uptake of newer LAIs.
controlled trial compared adjunctive benzoate (1 g/day) plus sarcosine (2 g/day) vs. sarcosine (2 g/day) for clinical symptoms, cognitive function, and global functioning of chronic schizophrenia patients who have been stabilized with various second-generation antipsychotics. Participants were measured with the Positive and Negative Syndrome Scale and the Global Assessment of Functioning Scale every 3 weeks. Seven cognitive domains, recommended by the Measurement and Treatment Research to Improve Cognition in Schizophrenia Committee, were measured at weeks 0 and 12. Results: Combination of both NMDA-enhancing agents, rather than sarcosine alone or placebo, improved global functioning and the global composite score of all 7 cognitive domains of patients with schizophrenia while their clinical symptoms remained unimproved. Discussion: Our previous study showed that add-on benzoate improved cognitive function and clinical symptoms of chronic schizophrenia patients who had been stabilized at haloperidol or risperidone. Whether the cognitive improvement was secondary to symptom reduction remained uncertain. The findings of the current study plus the previous study suggest that NMDAenhancement therapy can improve the cognitive function of patients with schizophrenia, supporting the pro-cognitive effect can be primary no matter whether clinical symptoms improve or not. 
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Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia 
Method:
A total 52 patients with antipsychotics-induced hyperprolactinemia were recruited. Aripiprazole was added to patients with mild hyperprolactinemia (serum prolactin level lower than 50ng/ml). Patients with severe hyperprolactinemia (serum prolactin level higher than 50ng/ml) were randomized to aripiprazole addition group (adding aripiprazole to previous antipsychotics) or switching group (switching previous antipsychotics to aripiprazole). Serum prolactin levels, menstrual disturbances, sexual dysfunctions, psychopathologies, quality of life were measured at weeks 0, 1, 2, 4, 6 and 8. Results: Both addition and switching strategies significantly reduced serum prolactin levels (F(1, 199) =4.31, df=1, p=0.04) in switching group was significantly lower than that in addition group at week 8. Conclusion: Both addition and switching strategies were effective in resolving antipsychotics-induced hyperprolactinemia and hyperprolactinemia related adverse events including menstrual disturbances and sexual dysfunctions. These findings suggest that switching to aripiprazole may be more effective in normalizing hyperprolactinemia and improving hyperprolactinemia related adverse events in patients with schizophrenia.
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